DOGWOOD THERAPEUTICS INC · Data as of 2026-09-08
2026
The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron ® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year , " said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics.Source filing
fall 2026
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –Source filing
Late 2026
Submitting our end of Phase 2 summary, manufacturing plans and Phase 3 clinical development plans to FDA towards the end of 2026, assuming favorable outcomes in our ongoing Halneuron ® Phase 2b program.Source filing
Fall 2026
Currently, we have enrolled 217 patients and expect top-line data from the trial in the fall of 2026.Source filing